DiaCarta

DiaCarta is a translational genomics and precision molecular diagnostics company established in 2011. It aims to provide highly sensitive and advanced technologies that will enhance the impact of molecular diagnostics and translational genomics on healthcare programs and global individual well-being. With over 80 global patents, DiaCarta offers a range of products and services, including single-gene cancer mutation detection qPCR assays, colorectal cancer mutation detection panels, cfDNA tests for monitoring radiotherapy toxicity, and targeted NGS panels. Equipped with more than 14,600 square feet of dedicated GMP-compatible laboratory space, and certified by CLIA and ISO 13485, DiaCarta has clinical laboratory facilities in Nanjing and an office in Shanghai, China. Fully equipped, DiaCarta is capable of serving clinical laboratories worldwide. The DiaCarta Clinical Service Laboratory in Nanjing, China, is one of the largest sequencing centers globally, equipped with several precision sequencing instruments. The company is currently participating in the "Million Genomes Project," which plans to conduct whole-genome sequencing (WGS) for one million Chinese individuals.